NuVasive released a statement touting the potential for business growth as a result of the tax bill, which reduces the U.S. corporate tax rate from 35 percent to 21 percent; prior to the bill, NuVasive projected its tax rate would be 33 percent on a non-GAAP basis next year.
“The savings from the landmark decision are expected to boost forward-looking free cash flow and non-GAAP EPS well in excess of 10 percent per year beginning in 2018, delivering incredible incremental value-generating opportunities for our shareholders,” said Gregory Lucier, chairman and CEO of NuVasive.
NuVasive expects to accelerate innovation as a result of the tax savings and explore additional growth opportunities. The company expects the new regulations to positively impact non-GAAP earnings per share and an early analysis indicates its non-GAAP tax rate to drop into the low 20 percent range for 2018.
The company plans to invest its surplus funds into research and development. “This is a tremendous opportunity for the medical device industry, and a major spark in our ability to continue to invest in life-changing innovations,” said Mr. Lucier.
More articles on spine devices:
Medtronic changes leadership with 2 executive appointments—6 things to know
Barrow Neurological Institute & Aesculap to hold live neurosurgery courses: 5 things to know
Spineology adds Richard Nigon to board of directors: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
